purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation crmd earnings call period ending december image source motley fool cormedix crmd q earnings callmar etcontents prepared remark question answer call participant prepared remark operatorgood morning lady gentleman welcome cormedix inc fourth quarter full year earnings call time line listenonly mode following presentation conduct questionandanswer session operator instruction call recorded march would like turn conference dan ferry lifesci advisor please go aheaddan ferry investor relation good morning welcome cormedixs full year earnings conference call leading call today joe todisco chief executive officer cormedix joined dr matt david executive vice president cfo beth zelnick kaufman evp chief legal officer liz hurlburt evp chief clinical strategy operation officer erin mistry evp chief commercial officer begin would like remind everyone call management may make known forwardlooking statement within meaning set forth private security litigation reform act statement subject certain risk uncertainty include limited following statement statement historical fact regarding management expectation belief goal plan company prospect including commercial launch prospect defencath clinical development program expanded us defencath manufacturing activity marketing approval product candidate future financial position future revenue projected cost reimbursement potential market acceptance defencath product candidate actual result may differ materially projection estimate due variety important factor including limited uncertainty related clinical development regulatory approval commercialization risk described greater detail cormedix filing sec including latest quarterly report form q annual report form k copy available free charge sec website wwwsecgov upon request cormedix cormedix may actually achieve goal plan described forwardlooking statementsinvestors place undue reliance statement please note cormedix intend update forwardlooking statement except required law time pleasure turn call joe todisco chief executive officer cormedix joe please go ahead joe todisco chief executive officer thanks dan good morning everyone thank joining u call since last presented earnings november company achieved number key milestone notably final nda approval defencath yous fda well confirmation cm defencath eligible receive transitional drug addon payment tdapa outpatient reimbursement cm classified defencath renal dialysis service endstage renal disease prospective payment system previously announced submitted hcpcs jcode application cm december tdapa application january following receipt reimbursement guidance cm application remain review cm cm confirmed writing actively reviewing jcode tdapa application working toward july effective implementation defencath tdapa payment said cm reserve right request additional information application may impact review timing andor probability jcode tdapa jcode approved effective tdapa application gating item outpatient commercial launch defencath currently slated july st company remains schedule commence commercial launch inpatient setting april th staffed trained field sale medical affair organization held successful internal team launch meeting last week february team built deeply experienced specialized background infectious disease nephrology spanning inpatient outpatient setting care also ramping inventory production accordance internal plan heavily weighted toward back part year part supply chain strategy company track submit supplement nda april qualifying siegfried site hameln germany alternative manufacturing site defencath assuming favorable fda review supplement additional production site would come online end think inpatient launch trajectory april expect ramp inpatient utilization fairly modest first two launch quarter inpatient health system hospital working respective pt formulary review process average pt process particular system hospital range three nine month said received significant interest last month actively working pt process several large midsized health system expect activity intensify coming month fieldbased key account manager begun calling hospital health system effectuate prelaunch contracting discussion outpatient side continue productive discussion large midsized dialysis operator look forward providing additional update coming month discussion advance based upon current force current base case forecast continue believe company achieve breakeven profitability run rate basis end december assuming able achieve internal base case assumption defencath demand uptake net pricing reimbursement believe sufficient cash resource hand achieve objective however launch uptake defencath slower internal projection requiring capital believe several financing alternative available company including nondilutive source financing cormedix grown size addition new hire field sale medical affair well addition across organization thankful involved latest expansion new team member work gone preparing company anticipated commercial launch proud accomplished recent month excited bring defencath patient would like turn call matt discus company fourth quarter yearend financial result financial position mattmatt david executive vice president chief financial officer thanks joe good morning everyone pleased today provide overview fourth quarter full year financial result well update cormedixs cash position company filed annual report form k year ended december urge read information contained report complete discussion financial result respect fourth quarter financial result net loss approximately million per share compared loss million per share fourth quarter higher net loss recognized compared primarily driven increase cost related market research study prelaunch activity defencath increase personnel expense due new hire compared period operating expense fourth quarter increased approximately million compared million fourth quarter rd expense decreased approximately million driven primarily decrease manufacturing cost related defencath sga expense increased approximately million fourth quarter compared million fourth quarter increase primarily attributable increase cost related launch activity higher personnel cost due additional hire q respect full year financial result total operating expense full year amounted million compared million increase rd expense increased million driven primarily increase personnel expense increase cost related medical affair activity increase cost related technical quality operation manufacturing defencath prior marketing approval sga expense increased approximately million primarily driven increase cost related market research study prelaunch activity preparation commercial launch defencath increase personnel expense result additional hire increase partially offset among others lesser significance decrease legal fee period recorded net cash used operation million compared net cash used operation million increase primarily driven increase net loss primarily attributable increase operating expense compared period cormedix remains good position balance sheet perspective prepare company commercial launch defencath april company cash cash equivalent million december discussed previously expect operating expense especially sga increase given growth company cost driven commercial launch defencath cormedix anticipates quarterly operating expense range around million million support commercial infrastructure launch defencath believe cash cash equivalent shortterm investment projected future operating cash flow give company ability fund operation least month fund commercial launch defencath anticipated profitability may occur run rate basis end december assuming able achieve internal base case assumption defencath demand uptake net pricing reimbursement turn call back joe closing remark joejoe todisco chief executive officer thanks matt cormedix laserfocused upcoming launch date april actively engaged customer discussion inpatient outpatient setting care optimistic launch potential beyond respect future potential indication defencath targeting submission postapproval meeting request fda end march expect meaningful discussion fda around potential clinical pathway midyear mentioned earlier intend provide revenue earnings guidance time however may revisit guidance appropriate appreciate everyone continued support cormedix happy take question question answer operatorthank lady gentleman begin questionandanswer session operator instruction first question coming line jason butler citizen jmp please go aheadjason butler jmp security analyst hi thanks taking question congrats progress wondering could give u little bit detail progress making hospital pt committee meeting scheduled point think get think get first decision meeting secondly walk u think early launch utilization within hospital get know committee meeting approval mean expect use get first committee approval thanksjoe todisco chief executive officer yeah thanks jason pt meeting process meeting currently scheduled number expect scheduled let u say second quarter really comment timing know quickly move whether adopted formulary way would think inpatient even touch outpatient second know mentioned would slower ramp right due pt process think short term long term know think inpatient side kind steady gradual ramp whereas outpatient side given know potential size certain large customer well even ability midsized customer move volume would expect ramp little lumpy right outpatient side know see maybe new patient start within facility focusing initially feeforservice patient right know begin onboard plan time would little bit kind step right lumpy upward rampjason butler jmp security analyst got one term label expansion activity catheteruse setting obviously mentioned waiting fda interaction feedback operational perspective guy preparing position launch trial start trial quickly get fda alignmentjoe todisco chief executive officer obviously going depend whether adopt proposal intend make right think accepting pathway going put forward know certain expanded indication launch fairly quickly immediate right flipping light switch know know desire work done could longer pathwayjason butler jmp security analyst ok great thanks taking questionsoperatorthank next question come line gregory renza rbc capital market go ahead pleaseanish nikhanj rbc capital market analyst hi joe team anish greg congrats progress quarter thanks taking question first maybe could give u update current composition commercial field force granularity new add inpatient outpatient segment date secondly thinking current upcoming shift political tide affecting cm reimbursement policy pertains defencath thanks againjoe todisco chief executive officer right thanks anish field team standpoint migrated little bit think thinking last year rather bifurcation inpatient outpatient team somewhat melded one geographic deployment important let u say split two setting care know given nature role key account manager medical rep essentially skill set side care reimbursement knowledge contracting standpoint hurdle side really getting product adopted system large system small dialysis operator right staffed field think sufficient launch may look grow time range right comfortable right team place know political standpoint really hard tell right may happen certainly know four year experience biden white house gone experience cm also four year past experience trump administration time really seeing anything drastically change cm regardless end white house know certainly could always changeanish nikhanj rbc capital market analyst great thank youoperatorthank next question come line le sulewski truist security please go aheadles sulewski truist security analyst good morning thank taking question joe provide color around distribution channel around commercial inventory level ahead launch expect inpatient center manage stocking level maybe implied ratio expected demand ml versus ml vial also followup one quarter would expect manufacturing cost shift rd cogsjoe todisco chief executive officer thanks le good question distribution channel standpoint know essentially inventory going flow specialty distribution inpatient side inpatient facility flow specialty distributor outpatient side mix going specialty distributor customer others potentially go get shipped direct ml ml issue ml label done initial development work remember product initially ml vial intent commercialize ml time launching intent launch product ml know last question asked cut difficult one right depends uptake demand think faster demand go could certainly see cut earlier right year right demand little bit slower may take time right built decent amount inventory pre right expensed right prior approvalles sulewski truist security analyst got thanksjoe todisco chief executive officer inaudibleles sulewski truist security analyst inaudible followup joe todisco chief executive officer yeahles sulewski truist security analyst think yes one followup guess strategy around separate payment medicare part b reimbursement potential timeline filing approval expect potential impact wac pricejoe todisco chief executive officer yeah sure followed question le outpatient reimbursement determination cm made determination eligible tdapa right going fall scope end stage esrd prospective payment system inpatient side ntap jcode application required tdapa right jcode might thinking separate part b determination clarify question lesles sulewski truist security analyst correct potential adjustment wac pricejoe todisco chief executive officer look launched product wac time envision adjustment wac price tdapa period always reevaluate move forwardles sulewski truist security analyst got thank youoperatorthank next question come line serge belanger needham company please go aheadserge belanger needham company analyst hi good morning thanks taking question joe think mentioned pt review process would take three nine month maybe talk little bit process entail outpatient setting also expect kind adoption process evaluation process uptake maybe lastly walk u base case breakeven end year thanksjoe todisco chief executive officer ok going start number three first going allow erin comment pt process facility know certainly outpatient think asking second question outpatient know follow similar evaluation process making determination put product formulary utilization right looking clinical data product looking medical need certainly reimbursement facility well whatever economic term able provide institution know think asking number three clarify asking confirm get run rate breakeven question threeserge belanger needham company analyst really push pull get breakeven status talked base casejoe todisco chief executive officer ok yes sure mean look certain assumption made demand uptake inpatient outpatient side right produce revenue forecast internally cash flow forecast comfortable get u run rate breakeven profitability mentioned think going provide granularity time whereas said going give revenue guidance certainly think know math given guidance run rate operating expense going somewhat back revenue really need order hit milestone erin want provide erin mistry executive vice president chief commercial officer sure provide little bit color around pt process process driven hospital internally right usually physician champion advocate product formulary meeting happens adopt product go process implementing within health system seen lot interest product organically inorganically right done reachouts also reachouts hospital u think benefit secured ntap prior approved opportunity leverage payment mechanism inpatient side also opportunity leverage health economics right longterm complication patient hospital one one see patient expense lot organic inorganic interest hospitalsjoe todisco chief executive officer thanks erin serge answer questionserge belanger needham company analyst yup thank youoperatorthank turn call back dan ferry written question audiencedan ferry investor relation thank operator joe written question audience first one ntap approved based estimated wac price per vial however launched product actual wac per vial explain explain impact ntap reimbursement expect price point positive negative impact inpatient utilization color provide around lower wac decidedjoe todisco chief executive officer ok thanks dan lot unpack going start taking step back thought process around established price point right filed ntap application two year ago market landscape looked different specifically outpatient side right tdapa two year necessarily visibility outpatient utilization market analysis market research around product would need priced inpatient side alone size inpatient market ultimately settled price know since time obviously landscape shifted tdapa five year number conversation customer setting care last two year outpatient side specifically gotten much comfortable confident around ability first secure reimbursement tdapa second get sufficient uptake wac price established really driven dynamic tdapa outpatient segment reasonable price point inpatient one key piece feedback took last two year inpatient institution message around ntap value ntap many institution perceive lower acquisition cost product preferred higher ntap reimbursement extent feedback gotten inpatient side lower wac price favorable think question asked know expect price point positive negative impact utilization feedback getting lower acquisition cost product drive higher utilization inpatient side certainly happy thatdan ferry investor relation ok great thanks joe second question expected study data presented coming month give investor sense conference cormedix may presencejoe todisco chief executive officer yeah thanks going turn liz moment know got pretty ambitious planned field organization active number industry conference liz go aheadliz hurlburt executive vice president clinical medical affair sure thanks joe yes excited actually going presenting two abstract spring upcoming society healthcare epidemiology america shea annual meeting field team medical commercial going present dozen conference year continuing connect key stakeholder know include shea madid nkf spring conference renal physician association think really good presence theredan ferry investor relation ok great thanks liz joeliz hurlburt executive vice president clinical medical affair yeah ok yupdan ferry investor relation joe final question give sense investor may missing key understanding cormedix near termjoe todisco chief executive officer ok thanks dan look assume thinking stock price trading standpoint know still think story completely widely understood right niche therapeutic segment atypical reimbursement lot acronym talk ntap tdapa necessarily common vernacular biotech investor also know young biotech going first launch think historically lot investor kind sat sideline waiting know new equity offering know discussed today focused launch think lot launch value defencath certainly captured trading value stock also think potentially longterm value year exclusivity expecting meet fda know midyear around label expansion defencath think importantly next couple year know expectation developing realworld evidence demonstrating impact impact defencath infection rate patient certainly look utilize realworld data one obviously established broader utilization also longterm reimbursement across continuum caredan ferry investor relation ok great thanks joe operator concludes written portion qa session may close calloperatoroperator signoff duration minutescall participantsdan ferry investor relationsjoe todisco chief executive officermatt david executive vice president chief financial officerjason butler jmp security analystanish nikhanj rbc capital market analystles sulewski truist security analystserge belanger needham company analysterin mistry executive vice president chief commercial officerliz hurlburt executive vice president clinical medical affair crmd analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool position stock mentioned motley fool disclosure policy